Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives
- PMID: 24867680
- DOI: 10.1586/14760584.2014.924404
Glycan surface antigens from Bacillus anthracis as vaccine targets: current status and future perspectives
Erratum in
-
Erratum.Expert Rev Vaccines. 2015;14(8):1159. doi: 10.1586/14760584.2015.1070000. Expert Rev Vaccines. 2015. PMID: 26172372 No abstract available.
Abstract
Over recent years great attention has been directed to the discovery of novel antigens from Bacillus anthracis, because of the potential of its spores in the development of weapons for mass destruction. Substantial effort has been directed to the identification and immunochemical evaluation of glycans that might be used for specific diagnostic detection of the spores or immune-mediated prevention of anthrax. Carbohydrate structures found on surfaces of vegetative cells and spores are herein discussed. Among them, the cell wall polysaccharide and the tetrasaccharide unit isolated from the exosporium protein BclA were proven immunogenic in an animal model after covalent linkage to carrier protein. Further investigation is needed to fully assess the potential of these promising carbohydrate antigens for vaccine development.
Keywords: anthrax; carbohydrates; cell wall polysaccharide; exosporium; glycoconjugates; peptidoglycan.
Similar articles
-
BclA and toxin antigens augment each other to protect NMRI mice from lethal Bacillus anthracis challenge.Vaccine. 2015 Jun 4;33(24):2771-7. doi: 10.1016/j.vaccine.2015.04.049. Epub 2015 Apr 24. Vaccine. 2015. PMID: 25917676
-
Protection of farm goats by combinations of recombinant peptides and formalin inactivated spores from a lethal Bacillus anthracis challenge under field conditions.BMC Vet Res. 2017 Jul 12;13(1):220. doi: 10.1186/s12917-017-1140-2. BMC Vet Res. 2017. PMID: 28701192 Free PMC article.
-
Recombinant Bacillus anthracis spore proteins enhance protection of mice primed with suboptimal amounts of protective antigen.Vaccine. 2008 Sep 8;26(38):4927-39. doi: 10.1016/j.vaccine.2008.07.015. Epub 2008 Jul 25. Vaccine. 2008. PMID: 18657585 Free PMC article.
-
Progress and novel strategies in vaccine development and treatment of anthrax.Immunol Rev. 2011 Jan;239(1):221-36. doi: 10.1111/j.1600-065X.2010.00969.x. Immunol Rev. 2011. PMID: 21198675 Review.
-
Anthrax vaccines: a development update.BioDrugs. 2005;19(4):233-45. doi: 10.2165/00063030-200519040-00003. BioDrugs. 2005. PMID: 16128606 Review.
Cited by
-
Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines.ACS Infect Dis. 2023 Feb 10;9(2):178-212. doi: 10.1021/acsinfecdis.2c00559. Epub 2023 Jan 27. ACS Infect Dis. 2023. PMID: 36706246 Free PMC article. Review.
-
Structure-Immunogenicity Relationship of α- and β-Tetrasaccharide Glycoforms from Bacillus anthracis Exosporium and Fragments Thereof.Molecules. 2018 Aug 20;23(8):2079. doi: 10.3390/molecules23082079. Molecules. 2018. PMID: 30127242 Free PMC article.
-
Synthetic carbohydrate-based vaccines: challenges and opportunities.J Biomed Sci. 2020 Jan 3;27(1):9. doi: 10.1186/s12929-019-0591-0. J Biomed Sci. 2020. PMID: 31900143 Free PMC article. Review.
-
Emerging facets of prokaryotic glycosylation.FEMS Microbiol Rev. 2017 Jan;41(1):49-91. doi: 10.1093/femsre/fuw036. Epub 2016 Aug 26. FEMS Microbiol Rev. 2017. PMID: 27566466 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
